This section includes information and resources about Cardiovascular Disease for journalists: Boehringer Ingelheim press releases, background information, related press kits and a collection of images and videos.
Telmisartan (Micardis®) as effective as ramipril but with better long-term tolerability in high-risk cardiovascular Asian patients
First landmark ARB trial against placebo shows Micardis® (telmisartan) reduces the risk of cardiovascular death, heart attack and stroke in ACE-intolerant high-risk patients
Landmark trial ONTARGET proves telmisartan is as protective as ramipril and better tolerated in a broad high-risk cardiovascular population. From ONTARGET® it may be concluded that telmisartan can prevent every 5th serious cardiovascular event.